You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
In its complaint, the Maryland-based company claimed that Natera infringes two of its patents, both titled "Methods for detection of genetic disorders."
The panel's developers at UPenn hope to validate and commercialize a non-invasive assay through a startup called Chip Diagnostics.
The plaintiffs allege that TAI's heart transplant rejection test MyTAIHeart infringes on their patent for the non-invasive diagnosis of graft rejection.
Investigators reported on how ctDNA, measured using Natera's patient-specific Signatera assays, corresponded to a patient's disease progression and other biomarkers.
Researchers published the most comprehensive data to date showing that Grail's screening approach can detect and distinguish a significant number of cancers.
The San Francisco-based startup believes that its QiSant assay could help guide the use of immunosuppressive drugs and other therapies to prevent kidney transplant rejection.
The US Court of Appeals for the Federal Circuit sent the case, which had been thrown out in December 2018, back to the trial court.
The firm argues that its tests allows hospitals to expedite patient treatment, while curbing the costs of one-off tests and medication, and minimizing the length of a patient's stay.
A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.
The firm will use the funding to expand access to its microbial cell-free DNA technology to help doctors diagnose infectious disease.